• 
  • Login
  • Nieuwsbrief
  • Joseph Calabrese, MD

    Update on Lurasidone for Bipolar Depression

  • Paul E. Keck, MD

    Update on Binge Eating Disorder

  • Angelo Sambunaris, MD

    Update on the Anxiolytic Effects of Vilazodone

  • Ashwin A. Patkar, MD

    Switching Strategies to Different Doses of Vilazodone

  • Rakesh Jain, MD

    Role of L-Methylfolate as an Adjunct in Treatment Resistant Depression

  • Dan V. Iosifescu, MD

    Rapidity of Response to Lurasidone in Bipolar Depression

  • Connie Sánchez, MD

    Preclinical Profile of Vortioxetine and Role in Cognition

  • Ronald Black, MD

    Pharmacotherapy of Borderline Personality Disorder

  • Susan L. McElroy, MD

    Metabolic Effects of Lurasidone

  • Ronald Black, MD

    Management of Antisocial Personality Disorder

  • Michael Ostacher, MD

    LITMUS and BALANCE Studies

  • Andrew Cutler, MD

    Levomilnacipran and Functional Improvement in Major Depression

  • Eduard Vieta, MD

    ISBD Guidelines for Antidepressant Use in Bipolar Disorder

  • Roger McIntyre, MD

    Innovative Strategies for Treating Cognitive Disturbances in Major Depression

  • Eduard Vieta, MD

    Role of Functional Remediation in Bipolar Disorder

  • Patrick McGorry, MD

    Early Interventions in Psychosis

  • Joseph Biederman, MD

    Controversies Surrounding Paediatric Bipolar Disorder

  • Thomas R. Weiss, MD

    Clinical Pearls in Psycho-Oncology

  • John M. Zajecka, MD

    Clinical Implications of Cognitive Disturbances in Major Depression

  • Edwin F. Torrey, MD

    Challenges to Mental Health Treatment in the US

  • Michael E. Thase, MD

    Brexipiprazole as an Adjunct in Treatment Resistant Depression